Skip to main content

Table 1 Subject characteristics

From: Treatment effects of stimulant medication in young boys with fragile X syndrome

Age (years)

IQ

Medication

Dose

CBCL T score

% Time attending

% Time out of seat

DSM-ADHD

Attention problems

On medication

Off medication

On medication

Off medication

5

76

Methylphenidate

0.10 mg/kg A.M.

58

66a

64

80

84

57

6

76

Methylphenidate

0.10 mg/kg A.M.

69a

75b

92

57

35

8

6

73

Dextroamphetamine

0.025 mg/kg A.M.

50

53

68

59

1

0

7

54

Methylphenidate

0.10 mg/kg A.M.

58

64

98

58

0

37

8

48

Methylphenidate

0.05 mg/kg A.M.

56

57

85

73

0

0

9

68

Methylphenidate

0.15 mg/kg A.M.

58

67a

92

92

42

17

9

60

Dextroamphetamine

0.30 mg/kg A.M.

58

66a

85

96

1

2

9

48

Dextroamphetamine

0.10 mg/kg A.M.

51

55

88

80

0

0

10

42

Methylphenidate

0.20 mg/kg A.M.

50

57

87

58

<1

0

10

52

Methylphenidate

0.45 mg/kg daily

60

71b

55

38

0

0

10

44

Dextroamphetamine

Dailyc

66a

66a

93

69

2

32

11

42

Methylphenidate

0.25 mg/kg A.M.

62

67a

91

93

0

11

  1. CBCL T scores ranges: normal (<65)
  2. aBorderline (65–69), CBCL T scores range
  3. bClinical (>69), CBCL T scores range
  4. cDosage for one participant was missing due to incomplete parent report